Based on the Beauty Health Co stock forecast from 2 analysts, the average analyst target price for Beauty Health Co is USD 1.58 over the next 12 months. Beauty Health Co’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Beauty Health Co is Slightly Bearish, which is based on 4 positive signals and 8 negative signals. At the last closing, Beauty Health Co’s stock price was USD 1.73. Beauty Health Co’s stock price has changed by +0.00% over the past week, +94.38% over the past month and -34.47% over the last year.
No recent analyst target price found for Beauty Health Co
No recent average analyst rating found for Beauty Health Co
Company Overview Beauty Health Co
The Beauty Health Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells esthetic technologies and products in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers. The Beauty Health Company was founded in 1997 and is headquartered in Long Beach, California. Read Less
The Beauty Health Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells esthetic technologies and products in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. The company's flagship product is HydraFacial, which enhances ...Read More
Frequently Asked Questions About Beauty Health Co (SKIN) Stock
Based on ratings from 2 analysts Beauty Health Co's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on SKIN's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for SKIN is USD 1.58 over the next 12 months. The maximum analyst target price is USD 2 while the minimum anlayst target price is USD 1.25.
SKIN stock's Price/Earning ratio is 46.15.
Our analysis grades SKIN stock's Price / Earning ratio at F. This means that SKIN stock's Price/Earning ratio is above 78% of the stocks in the Household & Personal Products sector in the NSD exchange.
Based on this SKIN may be a overvalued for its sector.
The last closing price of SKIN's stock was USD 1.73.
The most recent market capitalization for SKIN is USD 0.13B.
Based on targets from 2 analysts, the average taret price for SKIN is projected at USD 1.58 over the next 12 months.
This means that SKIN's stock price may go down by -8.48% over the next 12 months.
We can't find any ETFs which contains Beauty Health Co's stock.
As per our most recent records Beauty Health Co has 769 Employees.
Beauty Health Co's registered address is 2165 Spring Street, Long Beach, CA, United States, 90806.
You can get more information about it from Beauty Health Co's website at https://www.beautyhealth.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Beauty Health Co (SKIN) Stock
Based on ratings from 2 analysts Beauty Health Co's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on SKIN's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for SKIN is USD 1.58 over the next 12 months. The maximum analyst target price is USD 2 while the minimum anlayst target price is USD 1.25.
SKIN stock's Price/Earning ratio is 46.15.
Our analysis grades SKIN stock's Price / Earning ratio at F. This means that SKIN stock's Price/Earning ratio is above 78% of the stocks in the Household & Personal Products sector in the NSD exchange.
Based on this SKIN may be a overvalued for its sector.
The last closing price of SKIN's stock was USD 1.73.
The most recent market capitalization for SKIN is USD 0.13B.
Based on targets from 2 analysts, the average taret price for SKIN is projected at USD 1.58 over the next 12 months.
This means that SKIN's stock price may go down by -8.48% over the next 12 months.
We can't find any ETFs which contains Beauty Health Co's stock.
As per our most recent records Beauty Health Co has 769 Employees.
Beauty Health Co's registered address is 2165 Spring Street, Long Beach, CA, United States, 90806.
You can get more information about it from Beauty Health Co's website at https://www.beautyhealth.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SKIN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
